Taken together, across the studies depicted in these two tables, the incidence of hypothyroidism ranges from 0% [45] to 11% [41]) for anti-CTLA-4 mAbs, from 2.5% [44] to 10.19% [26] for anti-PD-1/anti-PD-L1 mAbs, and from 4% to 27% [44] for combination regimens. Here, CTLA4 is linked to hypothyroidism.